ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Hepatobiliary disorders associated with triazole antifungal agents: a disproportionality and Bayesian analysis based on the FAERS database.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study utilizes data from the FDA Adverse Event Reporting System (FAERS) to identify and compare adverse events (AEs) signals related to hepatobiliary disorders associated with triazole antifungal agents (TAAs), aiming to inform clinical selection and risk assessment of these drugs. AE reports related to TAAs submitted to the FAERS database from 2004Q1 to 2024Q4 were collected. Data mining was performed using multiple signal detection methods, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Bayesian Confidence Propagation Neural Network (BCPNN). The incidence of hepatobiliary-related AEs associated with the five TAAs was highest among individuals aged 45-64. Compared with other TAAs, the proportion of adverse events occurring in children is higher with voriconazole. For AEs related to voriconazole and isavuconazole, the proportion of males is higher than that of females, whereas for others, the proportion of male and female patients is roughly equal. Based on the prescribing information for each drug, a total of 11 novel AEs were identified across all TAAs, including hepatolysis (ROR = 11.73, PRR = 11.71), vanishing bile duct syndrome (ROR = 26.95, PRR = 26.94), hepatic fibrosis (ROR = 3.6, PRR = 3.6), venoocclusive liver disease (ROR = 7.6, PRR = 7.59), hepatosplenomegaly (ROR = 5.17, PRR = 5.17), hepatorenal syndrome (ROR = 4.85, PRR = 4.85), hepatic cysts (ROR = 6.59, PRR = 6.59), hepatomegaly (ROR = 3.5, PRR = 3.5), mixed liver injury (ROR = 7.71, PRR = 7.71), steatohepatitis (ROR = 22.49, PRR = 22.48), and hepatorenal failure (ROR = 11.02, PRR = 11.02). This study analyzed the clinical traits of hepatobiliary adverse event reports related to triazole antifungal agents, conducted a detailed comparative analysis of PT, and identified 11 novel PTs not mentioned in the drug labeling, such as vanishing bile duct syndrome, steatohepatitis, and hepatolysis. Clinicians should be alert to these novel risks and strengthen liver function monitoring during the clinical use of these drugs.
Indexed as
Identifiers
41111132What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.